Share Price and Basic Stock Data
Last Updated: November 22, 2025, 11:16 am
| PEG Ratio | -30.72 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Dhanvantri Jeevan Rekha Ltd operates in the Hospitals & Medical Services industry, with a market capitalization of ₹10.4 Cr and a current share price of ₹25.5. The company reported a steady increase in sales, rising from ₹16.77 Cr in FY 2022 to ₹17.68 Cr in FY 2023, and further projected to reach ₹20.46 Cr in FY 2024. This upward trajectory demonstrates the company’s resilience and potential in a competitive market. Quarterly sales figures show fluctuations, with a notable increase to ₹5.15 Cr in Dec 2023, illustrating a robust recovery from the pandemic’s impact. However, the sales figures are still below the ₹22.65 Cr target for FY 2025, indicating a need for strategic initiatives to maintain growth momentum. The company’s operating profit margin (OPM) stood at a modest 2.54%, suggesting operational inefficiencies compared to the typical sector margins seen in the healthcare industry, which usually range higher. Overall, Dhanvantri Jeevan Rekha Ltd is navigating a challenging landscape while gradually enhancing its revenue generation capabilities.
Profitability and Efficiency Metrics
The profitability metrics of Dhanvantri Jeevan Rekha Ltd reveal mixed results. The net profit for FY 2023 was recorded at ₹0.41 Cr, with a net profit margin of 2.25% in FY 2025, indicating a slight improvement but still reflecting challenges in cost management. The company’s return on equity (ROE) stood at 5.20% and return on capital employed (ROCE) at 5.82%, both of which are relatively low compared to industry standards. The interest coverage ratio (ICR) is remarkably high at 113.00x, showcasing the company’s strong ability to meet interest obligations, although it has not reported any borrowings. This suggests a conservative financial strategy, but the low profitability ratios highlight the need for operational efficiency improvements. Furthermore, the cash conversion cycle (CCC) of 29.01 days indicates a reasonable efficiency in managing working capital. However, with the OPM hovering around 2.54%, there is significant room for improvement in profitability through enhanced operational strategies.
Balance Sheet Strength and Financial Ratios
Dhanvantri Jeevan Rekha Ltd’s balance sheet reflects a cautious financial posture, with no reported borrowings, which positions it favorably in terms of financial leverage. The company’s book value per share has increased to ₹24.41 in FY 2025, indicating a strengthening of shareholder equity. The price-to-book value ratio (P/BV) stands at 0.84x, suggesting that the stock is trading below its book value, which could indicate an undervaluation relative to its assets. The current ratio of 1.46x indicates a solid liquidity position, suggesting that the company can comfortably meet its short-term liabilities. However, the low operating profit margin and net profit margin compared to industry averages raise concerns about the company’s operational efficiency. The earnings yield of 0.05 highlights a modest return for investors, further emphasizing the need for strategic improvements in profitability. Overall, while the balance sheet shows strength in terms of low debt levels, profitability remains a concern that needs to be addressed.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Dhanvantri Jeevan Rekha Ltd indicates a stable ownership structure, with promoters holding 19.65% of the shares and the public holding 80.35%. This distribution suggests a high level of public trust and engagement in the company, although the absence of foreign institutional investors (FIIs) and domestic institutional investors (DIIs) may reflect a lack of institutional confidence. The number of shareholders has shown a gradual increase, rising from 1,416 in Dec 2022 to 1,665 in Mar 2025, indicating growing interest among retail investors. However, the low promoter stake may raise questions regarding long-term commitment. The company’s ability to maintain and enhance shareholder value will depend on its operational performance and strategic initiatives that can drive profitability. The consistent retention of public interest, despite operational challenges, indicates a potential for investor confidence to grow if the company can demonstrate improved financial results.
Outlook, Risks, and Final Insight
Looking ahead, Dhanvantri Jeevan Rekha Ltd faces both opportunities and challenges. The projected revenue growth to ₹22.65 Cr for FY 2025 offers a positive outlook, provided the company can improve its operational efficiency and profitability metrics. Key strengths include a strong interest coverage ratio, indicating financial stability, and a healthy liquidity position. However, risks such as low profitability margins and reliance on public sentiment could hinder growth. Additionally, the absence of institutional backing may limit the company’s capital raising capabilities for expansion. To mitigate these risks, the company should focus on enhancing its operational efficiencies and exploring avenues for strategic partnerships. If successful, Dhanvantri Jeevan Rekha Ltd could transform its financial performance, leading to a stronger market position and increased investor confidence in the long term.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Dhanvantri Jeevan Rekha Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| NG Industries Ltd | 46.4 Cr. | 139 | 195/125 | 9.48 | 117 | 2.53 % | 23.6 % | 20.7 % | 10.0 |
| Global Longlife Hospital and Research Ltd | 21.2 Cr. | 20.2 | 35.5/18.3 | 24.3 | 0.00 % | 13.7 % | 17.7 % | 10.0 | |
| Gian Lifecare Ltd | 12.0 Cr. | 11.6 | 21.4/11.6 | 133 | 19.1 | 0.00 % | 3.00 % | 0.81 % | 10.0 |
| Fortis Malar Hospitals Ltd | 121 Cr. | 64.3 | 98.7/53.1 | 26.6 | 18.3 | 0.00 % | 0.83 % | 0.56 % | 10.0 |
| Family Care Hospitals Ltd | 21.5 Cr. | 3.98 | 7.60/3.40 | 1.51 | 0.00 % | 79.2 % | 85.5 % | 10.0 | |
| Industry Average | 27,996.36 Cr | 842.13 | 101.54 | 102.21 | 0.27% | 15.48% | 14.81% | 9.04 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 4.10 | 3.97 | 4.65 | 4.96 | 4.98 | 4.90 | 5.15 | 5.44 | 5.70 | 5.42 | 5.70 | 5.83 | 5.51 |
| Expenses | 3.86 | 4.04 | 4.48 | 4.73 | 4.75 | 4.87 | 4.68 | 5.43 | 5.45 | 5.18 | 5.51 | 5.79 | 5.37 |
| Operating Profit | 0.24 | -0.07 | 0.17 | 0.23 | 0.23 | 0.03 | 0.47 | 0.01 | 0.25 | 0.24 | 0.19 | 0.04 | 0.14 |
| OPM % | 5.85% | -1.76% | 3.66% | 4.64% | 4.62% | 0.61% | 9.13% | 0.18% | 4.39% | 4.43% | 3.33% | 0.69% | 2.54% |
| Other Income | 0.05 | 0.05 | 0.08 | 0.06 | 0.06 | 0.07 | 0.09 | 0.07 | 0.08 | 0.10 | 0.13 | 0.11 | 0.07 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.25 | 0.24 | 0.23 | 0.23 | 0.24 | 0.25 | 0.20 | 0.18 | 0.17 | 0.16 | 0.17 | 0.07 | 0.15 |
| Profit before tax | 0.04 | -0.26 | 0.02 | 0.06 | 0.05 | -0.15 | 0.36 | -0.10 | 0.16 | 0.17 | 0.15 | 0.08 | 0.06 |
| Tax % | 0.00% | 0.00% | 0.00% | 133.33% | 0.00% | 0.00% | 0.00% | -10.00% | 0.00% | 0.00% | 0.00% | 62.50% | 0.00% |
| Net Profit | 0.04 | -0.26 | 0.02 | -0.02 | 0.05 | -0.15 | 0.36 | -0.09 | 0.16 | 0.17 | 0.15 | 0.03 | 0.06 |
| EPS in Rs | 0.10 | -0.63 | 0.05 | -0.05 | 0.12 | -0.37 | 0.88 | -0.22 | 0.39 | 0.41 | 0.37 | 0.07 | 0.15 |
Last Updated: August 19, 2025, 8:10 pm
Below is a detailed analysis of the quarterly data for Dhanvantri Jeevan Rekha Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 5.51 Cr.. The value appears to be declining and may need further review. It has decreased from 5.83 Cr. (Mar 2025) to 5.51 Cr., marking a decrease of 0.32 Cr..
- For Expenses, as of Jun 2025, the value is 5.37 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 5.79 Cr. (Mar 2025) to 5.37 Cr., marking a decrease of 0.42 Cr..
- For Operating Profit, as of Jun 2025, the value is 0.14 Cr.. The value appears strong and on an upward trend. It has increased from 0.04 Cr. (Mar 2025) to 0.14 Cr., marking an increase of 0.10 Cr..
- For OPM %, as of Jun 2025, the value is 2.54%. The value appears strong and on an upward trend. It has increased from 0.69% (Mar 2025) to 2.54%, marking an increase of 1.85%.
- For Other Income, as of Jun 2025, the value is 0.07 Cr.. The value appears to be declining and may need further review. It has decreased from 0.11 Cr. (Mar 2025) to 0.07 Cr., marking a decrease of 0.04 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.15 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.07 Cr. (Mar 2025) to 0.15 Cr., marking an increase of 0.08 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.06 Cr.. The value appears to be declining and may need further review. It has decreased from 0.08 Cr. (Mar 2025) to 0.06 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Jun 2025, the value is 0.00%. The value appears to be improving (decreasing) as expected. It has decreased from 62.50% (Mar 2025) to 0.00%, marking a decrease of 62.50%.
- For Net Profit, as of Jun 2025, the value is 0.06 Cr.. The value appears strong and on an upward trend. It has increased from 0.03 Cr. (Mar 2025) to 0.06 Cr., marking an increase of 0.03 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.15. The value appears strong and on an upward trend. It has increased from 0.07 (Mar 2025) to 0.15, marking an increase of 0.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:31 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 7.26 | 7.97 | 9.26 | 11.16 | 13.74 | 16.84 | 18.21 | 9.78 | 16.77 | 17.68 | 20.46 | 22.65 | 22.46 |
| Expenses | 5.93 | 6.44 | 7.81 | 9.53 | 11.89 | 15.61 | 17.55 | 10.53 | 15.27 | 17.10 | 19.62 | 21.93 | 21.85 |
| Operating Profit | 1.33 | 1.53 | 1.45 | 1.63 | 1.85 | 1.23 | 0.66 | -0.75 | 1.50 | 0.58 | 0.84 | 0.72 | 0.61 |
| OPM % | 18.32% | 19.20% | 15.66% | 14.61% | 13.46% | 7.30% | 3.62% | -7.67% | 8.94% | 3.28% | 4.11% | 3.18% | 2.72% |
| Other Income | 0.21 | 0.44 | 0.31 | -0.11 | 0.14 | 0.12 | 0.16 | 0.18 | 0.21 | 0.24 | 0.29 | 0.41 | 0.41 |
| Interest | 0.01 | 0.08 | 0.08 | 0.18 | 0.22 | 0.11 | 0.04 | 0.02 | 0.02 | 0.01 | 0.01 | 0.01 | 0.01 |
| Depreciation | 0.67 | 0.36 | 0.27 | 0.37 | 1.10 | 1.13 | 1.10 | 1.04 | 1.02 | 0.96 | 0.87 | 0.56 | 0.55 |
| Profit before tax | 0.86 | 1.53 | 1.41 | 0.97 | 0.67 | 0.11 | -0.32 | -1.63 | 0.67 | -0.15 | 0.25 | 0.56 | 0.46 |
| Tax % | 39.53% | 29.41% | 32.62% | 43.30% | -7.46% | 63.64% | -15.62% | -12.88% | 28.36% | 46.67% | 36.00% | 8.93% | |
| Net Profit | 0.52 | 1.07 | 0.95 | 0.55 | 0.73 | 0.05 | -0.26 | -1.42 | 0.49 | -0.22 | 0.17 | 0.51 | 0.41 |
| EPS in Rs | 1.27 | 2.61 | 2.32 | 1.34 | 1.78 | 0.12 | -0.63 | -3.46 | 1.20 | -0.54 | 0.41 | 1.24 | 1.00 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 105.77% | -11.21% | -42.11% | 32.73% | -93.15% | -620.00% | -446.15% | 134.51% | -144.90% | 177.27% | 200.00% |
| Change in YoY Net Profit Growth (%) | 0.00% | -116.98% | -30.89% | 74.83% | -125.88% | -526.85% | 173.85% | 580.66% | -279.41% | 322.17% | 22.73% |
Dhanvantri Jeevan Rekha Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 11% |
| 5 Years: | 4% |
| 3 Years: | 11% |
| TTM: | 6% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | -6% |
| 5 Years: | 32% |
| 3 Years: | 1% |
| TTM: | 46% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 3% |
| 5 Years: | 26% |
| 3 Years: | 16% |
| 1 Year: | -9% |
| Return on Equity | |
|---|---|
| 10 Years: | 2% |
| 5 Years: | -1% |
| 3 Years: | 2% |
| Last Year: | 5% |
Last Updated: September 5, 2025, 3:11 pm
No data available for the Balance Sheet data table.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 16.09 | 15.11 | 20.50 | 11.45 | 17.80 | 22.32 | 9.02 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Inventory Days | 11.70 | 17.77 | 11.99 | |||||||||
| Days Payable | 0.00 | 0.00 | 0.00 | |||||||||
| Cash Conversion Cycle | 16.09 | 15.11 | 20.50 | 11.45 | 29.50 | 40.09 | 21.00 | 39.93 | 37.22 | 50.58 | 31.22 | 29.01 |
| Working Capital Days | 68.37 | 66.86 | 56.76 | -35.32 | -26.83 | -17.34 | -32.27 | -53.37 | -25.47 | -3.10 | -32.29 | -16.60 |
| ROCE % | 14.04% | 19.76% | 16.70% | 14.94% | 7.27% | 1.88% | -2.62% | -16.39% | 7.41% | -1.49% | 2.77% | 5.82% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Diluted EPS (Rs.) | 1.60 | 0.40 | -0.53 | 0.01 | -3.47 |
| Cash EPS (Rs.) | 2.58 | 2.48 | 1.78 | 3.63 | -0.91 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 24.41 | 22.81 | 22.41 | 22.93 | 21.75 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 24.41 | 22.81 | 22.41 | 22.93 | 21.75 |
| Revenue From Operations / Share (Rs.) | 54.58 | 49.26 | 42.58 | 40.38 | 23.55 |
| PBDIT / Share (Rs.) | 2.72 | 2.71 | 1.97 | 4.11 | -1.36 |
| PBIT / Share (Rs.) | 1.37 | 0.62 | -0.33 | 1.66 | -3.87 |
| PBT / Share (Rs.) | 1.35 | 0.61 | -0.34 | 1.62 | -3.92 |
| Net Profit / Share (Rs.) | 1.23 | 0.39 | -0.52 | 1.18 | -3.43 |
| PBDIT Margin (%) | 4.98 | 5.51 | 4.62 | 10.17 | -5.76 |
| PBIT Margin (%) | 2.51 | 1.27 | -0.77 | 4.11 | -16.44 |
| PBT Margin (%) | 2.47 | 1.24 | -0.81 | 4.01 | -16.66 |
| Net Profit Margin (%) | 2.25 | 0.80 | -1.22 | 2.92 | -14.55 |
| Return on Networth / Equity (%) | 5.03 | 1.74 | -2.32 | 5.14 | -15.75 |
| Return on Capital Employeed (%) | 4.90 | 2.33 | -1.25 | 5.69 | -16.04 |
| Return On Assets (%) | 3.45 | 1.10 | -1.56 | 3.41 | -11.11 |
| Long Term Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Total Debt / Equity (X) | 0.00 | 0.00 | 0.00 | 0.00 | 0.01 |
| Asset Turnover Ratio (%) | 1.52 | 1.42 | 1.25 | 1.23 | 0.71 |
| Current Ratio (X) | 1.46 | 1.30 | 1.24 | 1.66 | 0.74 |
| Quick Ratio (X) | 1.41 | 1.27 | 1.19 | 1.61 | 0.71 |
| Inventory Turnover Ratio (X) | 39.31 | 0.00 | 0.00 | 0.00 | 23.45 |
| Interest Coverage Ratio (X) | 113.00 | 224.14 | 117.93 | 104.40 | -26.69 |
| Interest Coverage Ratio (Post Tax) (X) | 52.00 | 33.85 | -30.24 | 30.99 | -66.31 |
| Enterprise Value (Cr.) | 6.02 | 7.20 | 4.55 | 5.13 | 2.26 |
| EV / Net Operating Revenue (X) | 0.26 | 0.35 | 0.25 | 0.30 | 0.23 |
| EV / EBITDA (X) | 5.33 | 6.38 | 5.56 | 3.01 | -4.01 |
| MarketCap / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| Price / BV (X) | 0.84 | 1.07 | 0.58 | 0.72 | 0.34 |
| Price / Net Operating Revenue (X) | 0.37 | 0.49 | 0.30 | 0.41 | 0.31 |
| EarningsYield | 0.05 | 0.01 | -0.04 | 0.07 | -0.45 |
After reviewing the key financial ratios for Dhanvantri Jeevan Rekha Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Diluted EPS (Rs.), as of Mar 25, the value is 1.60. This value is below the healthy minimum of 5. It has increased from 0.40 (Mar 24) to 1.60, marking an increase of 1.20.
- For Cash EPS (Rs.), as of Mar 25, the value is 2.58. This value is below the healthy minimum of 3. It has increased from 2.48 (Mar 24) to 2.58, marking an increase of 0.10.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.41. It has increased from 22.81 (Mar 24) to 24.41, marking an increase of 1.60.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 24.41. It has increased from 22.81 (Mar 24) to 24.41, marking an increase of 1.60.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 54.58. It has increased from 49.26 (Mar 24) to 54.58, marking an increase of 5.32.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.72. This value is within the healthy range. It has increased from 2.71 (Mar 24) to 2.72, marking an increase of 0.01.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.37. This value is within the healthy range. It has increased from 0.62 (Mar 24) to 1.37, marking an increase of 0.75.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.35. This value is within the healthy range. It has increased from 0.61 (Mar 24) to 1.35, marking an increase of 0.74.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 1.23. This value is below the healthy minimum of 2. It has increased from 0.39 (Mar 24) to 1.23, marking an increase of 0.84.
- For PBDIT Margin (%), as of Mar 25, the value is 4.98. This value is below the healthy minimum of 10. It has decreased from 5.51 (Mar 24) to 4.98, marking a decrease of 0.53.
- For PBIT Margin (%), as of Mar 25, the value is 2.51. This value is below the healthy minimum of 10. It has increased from 1.27 (Mar 24) to 2.51, marking an increase of 1.24.
- For PBT Margin (%), as of Mar 25, the value is 2.47. This value is below the healthy minimum of 10. It has increased from 1.24 (Mar 24) to 2.47, marking an increase of 1.23.
- For Net Profit Margin (%), as of Mar 25, the value is 2.25. This value is below the healthy minimum of 5. It has increased from 0.80 (Mar 24) to 2.25, marking an increase of 1.45.
- For Return on Networth / Equity (%), as of Mar 25, the value is 5.03. This value is below the healthy minimum of 15. It has increased from 1.74 (Mar 24) to 5.03, marking an increase of 3.29.
- For Return on Capital Employeed (%), as of Mar 25, the value is 4.90. This value is below the healthy minimum of 10. It has increased from 2.33 (Mar 24) to 4.90, marking an increase of 2.57.
- For Return On Assets (%), as of Mar 25, the value is 3.45. This value is below the healthy minimum of 5. It has increased from 1.10 (Mar 24) to 3.45, marking an increase of 2.35.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 0.2. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 0.00.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.52. It has increased from 1.42 (Mar 24) to 1.52, marking an increase of 0.10.
- For Current Ratio (X), as of Mar 25, the value is 1.46. This value is below the healthy minimum of 1.5. It has increased from 1.30 (Mar 24) to 1.46, marking an increase of 0.16.
- For Quick Ratio (X), as of Mar 25, the value is 1.41. This value is within the healthy range. It has increased from 1.27 (Mar 24) to 1.41, marking an increase of 0.14.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 39.31. This value exceeds the healthy maximum of 8. It has increased from 0.00 (Mar 24) to 39.31, marking an increase of 39.31.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 113.00. This value is within the healthy range. It has decreased from 224.14 (Mar 24) to 113.00, marking a decrease of 111.14.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 52.00. This value is within the healthy range. It has increased from 33.85 (Mar 24) to 52.00, marking an increase of 18.15.
- For Enterprise Value (Cr.), as of Mar 25, the value is 6.02. It has decreased from 7.20 (Mar 24) to 6.02, marking a decrease of 1.18.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 1. It has decreased from 0.35 (Mar 24) to 0.26, marking a decrease of 0.09.
- For EV / EBITDA (X), as of Mar 25, the value is 5.33. This value is within the healthy range. It has decreased from 6.38 (Mar 24) to 5.33, marking a decrease of 1.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 1. It has decreased from 1.07 (Mar 24) to 0.84, marking a decrease of 0.23.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.37. This value is below the healthy minimum of 1. It has decreased from 0.49 (Mar 24) to 0.37, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is 0.05. This value is below the healthy minimum of 5. It has increased from 0.01 (Mar 24) to 0.05, marking an increase of 0.04.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
Unable to fetch valid data for stock valuation.Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Dhanvantri Jeevan Rekha Ltd:
- Net Profit Margin: 2.25%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 4.9% (Industry Average ROCE: 15.48%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 5.03% (Industry Average ROE: 14.81%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 52
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 1.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 110 (Industry average Stock P/E: 101.54)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 2.25%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Hospitals & Medical Services | 1, Saket, Meerut Uttar Pradesh 250003 | dhanvantrihospital@gmail.com http://www.dhanvantrihospital.in |
| Management | |
|---|---|
| Name | Position Held |
| Mrs. Shalini Sharma | Managing Director |
| Mr. Premjit Singh Kashyap | Director |
| Mrs. Meenaakshi Elhence | Director |
| Mr. Tulsi Prasad Sharma | Director |
| Dr. Anil Elhence | Director |
| Mrs. Rowena Sharma | Director |
| Mr. Mohd Harris | Independent Director |
| Mr. Amitabh Krishna Bhatia | Independent Director |
| Mr. Ravi Karan | Independent Director |